News

Shire Plans Phase 4 Clinical Trial of Parathyroid Hormone Therapy

Shire plans a Phase 4 clinical trial of its parathyroid hormone therapy Natpara as an add-on to standard hypothyroidism treatment. Hypoparathyroidism is caused by abnormal low levels of parathyroid hormone (PTH), which regulates levels of calcium in blood and bones. Low levels of the hormone lead to a  mineral imbalance that…

Reduced Parathyroid Hormone Levels May Be Beneficial in PHP Patients, Study Finds

Treatment of patients with pseudohypoparathyroidism type 1B should involve lowering parathyroid hormone levels to avoid adverse effects on bone, according to a recent study. Pseudohypoparathyroidism (PHP) is a heterogeneous group of rare endocrine disorders characterized by normal renal function and resistance to the action of the parathyroid hormone — a hormone…

Hypoparathyroidism May Lead to Rare Neurological Disease, Case Study Suggests

Hypoparathyroidism may lead to the development of a rare neurological disorder manifesting with seizures, a case study reveals. The study, “A Case of Seizure Revealing Fahr’s Syndrome with Primary Hypoparathyroidism,” was published in the American Journal of Case Reports. The patient, a 52-year-old man, was admitted…

Emergency Card Helpful for Hypoparathyroidism Patients During an Acute Crisis, Study Says

Emergency cards can help ease the diagnosis and treatment of an acute crisis of low or high blood calcium levels among patients with…